MARKET

COLL

COLL

Collegium Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.78
-0.60
-2.94%
After Hours: 19.78 0 0.00% 16:00 10/20 EDT
OPEN
20.31
PREV CLOSE
20.38
HIGH
20.66
LOW
19.72
VOLUME
208.92K
TURNOVER
--
52 WEEK HIGH
25.59
52 WEEK LOW
11.19
MARKET CAP
682.92M
P/E (TTM)
-3803.8462
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Catalyst Pharmaceuticals Has Potential To Push Higher If They Can Overcome Current Headwinds
Catalyst Pharmaceuticals has dipped in recent months due to the lack of positive catalysts for the stock.This has brought renewed value to CPRX with Wall Street analysts predicting as much as 145% upside over the long term.Catalyst Pharma has reduced downside risks in comparison to other small-cap biotech plays as they already have an approved product on the market in Firdapse.
Seekingalpha · 6d ago
Collegium Pharmaceutical Inc (COLL): Hedge Funds Taking Some Chips Off The Table
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress. […]
Insider Monkey · 10/12 18:25
3 Top Healthcare Stocks You Can Buy Now for Less Than $40
MotleyFool.com · 10/04 06:51
Collegium settles Xtampza patent dispute with Teva
Collegium Pharmaceutical (COLL) has settled its patent infringement litigation with Teva Pharmaceutical Industries (TEVA) related to the latter's U.S. marketing application seeking approval of a generic version of abuse-deterrent opioid
Seekingalpha · 09/30 12:14
Collegium Appoints Rita Balice-Gordon to its Board of Directors
STOUGHTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Rita Balice-Gordon to its Board of Directors, effective September 24,
GlobeNewswire · 09/25 12:00
Collegium Announces Five Posters Presented at PAINWeek 2020 National Conference
STOUGHTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its product portfolio were presented
GlobeNewswire · 09/14 13:00
Collegium Announces Scientific Presentations at PAINWeek 2020 National Conference
STOUGHTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its product portfolio will be
GlobeNewswire · 09/09 20:05
Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -4.17% and 4.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 23:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of COLL. Analyze the recent business situations of Collegium Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average COLL stock price target is 28.00 with a high estimate of 35.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 227
Institutional Holdings: 38.56M
% Owned: 111.69%
Shares Outstanding: 34.53M
TypeInstitutionsShares
Increased
60
2.74M
New
43
-715.61K
Decreased
53
1.91M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Director
Michael Heffernan
President/Chief Executive Officer/Director
Joseph Ciaffoni
Chief Financial Officer/Executive Vice President
Paul Brannelly
Executive Vice President/Chief Technology Officer
Alison Fleming
Executive Vice President/General Counsel/Secretary
Shirley Kuhlmann
Executive Vice President
Scott Dreyer
Executive Vice President
Richard Malamut
Lead Director/Independent Director
Gino Santini
Director
Rita Balice-Gordon
Independent Director
Garen Bohlin
Independent Director
John Fallon
Independent Director
John Freund
Independent Director
Gwen Melincoff
Independent Director
Theodore Schroeder
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About COLL
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Collegium Pharmaceutical Inc stock information, including NASDAQ:COLL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COLL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading COLL stock methods without spending real money on the virtual paper trading platform.